Guan-Tarn Huang

Guan-Tarn Huang

Auto-generated profile, based on publicly available information

Guan-Tarn Huang

National Taiwan University Hospital, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2006 in JAMA
Verified
Journal Article
Closed access
PDF file
CCChien-Jen Chen
Chien-Jen Chen
HYHwai-I. Yang
Hwai-I. Yang
JSJun Su
Jun Su
SYSan-Lin You
San-Lin You
SLSheng-Nan Lu
Sheng-Nan Lu
UIUchenna H. Iloeje
Uchenna H. Iloeje
Research from JAMA — Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level — ContextSerum hepatitis B virus (HBV) DNA level is a marker of viral replication and efficacy of antiviral treatment in individuals with chronic hepatitis B.ObjectiveTo evaluate the relationship between serum HBV DNA level and risk of hepatocellular carcinoma.Design, Setting, and ParticipantsProspective cohort study of 3653 participants (aged 30-65 years), who were seropositive for the hepatitis B surface antigen and seronegative for antibodies against the hepatitis C virus, recruited to a community-based cancer screening program in Taiwan between 1991 and 1992.Main Outcome MeasureIncidence of hepatocellular carcinoma during follow-up examination and by data linkage with the national cancer registry and the death certification systems.ResultsThere were 164 incident cases of hepatocellular carcinoma and 346 deaths during a mean follow-up of 11.4 years and 41 779 person-years of follow-up. The incidence of hepatocellular carcinoma increased with serum HBV DNA level at study entry in a dose-response relationship ranging from 108 per 100 000 person-years for an HBV DNA level of less than 300 copies/mL to 1152 per 100 000 person-years for an HBV DNA level of 1 million copies/mL or greater. The corresponding cumulative incidence rates of hepatocellular carcinoma were 1.3% and 14.9%, respectively. The biological gradient of hepatocellular carcinoma by serum HBV DNA levels remained significant (P<.001) after adjustment for sex, age, cigarette smoking, alcohol consumption, serostatus for the hepatitis B e antigen (HBeAg), serum alanine aminotransferase level, and liver cirrhosis at study entry. The dose-response relationship was most prominent for participants who were seronegative for HBeAg with normal serum alanine aminotransferase levels and no liver cirrhosis at study entry. Participants with persistent elevation of serum HBV DNA level during follow-up had the highest hepatocellular carcinoma risk.ConclusionElevated serum HBV DNA level (≥10 000 copies/mL) is a strong risk predictor of hepatocellular carcinoma independent of HBeAg, serum alanine aminotransferase level, and liver cirrhosis.

1 January 2007 in Journal of the Formosan Medical Association
Verified
Journal Article
Closed access
CCChien-Hung Chen
Chien-Hung Chen
PYPei-Ming Yang
Pei-Ming Yang
GHGuan-Tarn Huang
Guan-Tarn Huang
HLHsuan-Shu Lee
Hsuan-Shu Lee
JSJuei-Low Sung
Juei-Low Sung
JSJin-Chuan Sheu
Jin-Chuan Sheu

1 July 2005 in Annals of Surgery
Verified
Journal Article
Closed access
GHGuan-Tarn Huang
Guan-Tarn Huang
PLPo-Huang Lee
Po-Huang Lee
YTYuk-Ming Tsang
Yuk-Ming Tsang
MLMing-Yang Lai
Ming-Yang Lai
PYPei-Ming Yang
Pei-Ming Yang
DCDing-Shinn Chen
Ding-Shinn Chen
To compare disease recurrence and survival among patients with small hepatocellular carcinoma after surgical resection or percutaneous ethanol injection therapy, 2 treatments that have not been evaluated with a prospective study. A total of 76 patients were randomly assigned to 2 groups based on treatment; all had one or 2 tumors with diameter

1 January 2018 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
WTWon Young Tak
Won Young Tak
SLShi-Ming Lin
Shi-Ming Lin
YWYijun Wang
Yijun Wang
JZJiasheng Zheng
Jiasheng Zheng
AVAldo Vecchione
Aldo Vecchione
RLRiccardo Lencioni
Riccardo Lencioni
Purpose: Lyso-thermosensitive liposomal doxorubicin (LTLD) consists of doxorubicin contained within a heat-sensitive liposome. When heated to ≥40°C, LTLD locally releases a high concentration of doxorubicin. We aimed to determine whether adding LTLD improves the efficacy of radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) lesions with a maximum diameter (dmax) of 3 to 7 cm. Experimental Design: The HEAT Study was a randomized, double-blind, dummy-controlled trial of RFA ± LTLD. The 701 enrolled patients had to have ≤4 unresectable HCC lesions, at least one of which had a dmax of 3 to 7 cm. The primary endpoint was progression-free survival (PFS) and a key secondary endpoint was overall survival (OS). Post hoc subset analyses investigated whether RFA duration was associated with efficacy. Results: The primary endpoint was not met; in intention-to-treat analysis, the PFS HR of RFA + LTLD versus RFA alone was 0.96 [95% confidence interval (CI), 0.79-1.18; P = 0.71], and the OS HR ratio was 0.95 (95% CI, 0.76–1.20; P = 0.67). Among 285 patients with a solitary HCC lesion who received ≥45 minutes RFA dwell time, the OS HR was 0.63 (95% CI, 0.41–0.96; P < 0.05) in favor of combination therapy. RFA + LTLD had reversible myelosuppression similar to free doxorubicin. Conclusion: Adding LTLD to RFA was safe but did not increase PFS or OS in the overall study population. However, consistent with LTLD's heat-based mechanism of action, subgroup analysis suggested that RFA + LTLD efficacy is improved when RFA dwell time for a solitary lesion ≥45 minutes. Clin Cancer Res; 1–11. ©2017 AACR.

1 September 1996 in Journal of Hepatology
Verified
Journal Article
Closed access
GHGuan-Tarn Huang
Guan-Tarn Huang
JSJin-Chuan Sheu
Jin-Chuan Sheu
PYPei-Ming Yang
Pei-Ming Yang
HLHsuan-Shu Lee
Hsuan-Shu Lee
TWTeh-Hong Wang
Teh-Hong Wang
DCDing-Shinn Chen
Ding-Shinn Chen

1 March 2003 in Stem Cells
Verified
Journal Article
Open access
PDF file
HLHsuan‐Shu Lee
Hsuan‐Shu Lee
GHGuan‐Tarn Huang
Guan‐Tarn Huang
HCHongsen Chiang
Hongsen Chiang
LCLing‐Ling Chiou
Ling‐Ling Chiou
MCMin-Huey Chen
Min-Huey Chen
CJChing-Chuan Jiang
Ching-Chuan Jiang
STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. STEM CELLS is read and written by clinical and basic scientists whose expertise encompasses the rapidly expanding fields of stem and progenitor cell biology. STEM CELLS welcomes original articles and concise reviews describing basic laboratory investigations of stem cells and the translation of their clinical aspects of characterization and manipulation from the bench to patient care. The journal covers all aspects of stem cells embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; stem cell technology: epigenetics, genomics, proteomics, and metabonomics; cancer stem cells; translational and clinical research; and regenerative medicine.